Chemotherapy News and Research

Latest Chemotherapy News and Research

EMEND indication helps women prevent CINV

More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy. Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting, CINV remains a significant problem in the context of current practice.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

Gentium first-quarter net loss decreases to EUR 0.03 million

Gentium S.p.A. today reported financial results for the quarter ended March 31, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP).

26 May 2010

Carolina Conceptions receives IRB approval to study on new egg freezing technology

Carolina Conceptions, an infertility practice in Raleigh, NC, announces IRB approval to commence a study on egg freezing - a newer technology that is growing in demand. While embryo and sperm freezing have been the standard of care for decades, egg freezing has been slower to achieve the same level of success.

26 May 2010

Breast-conserving therapy is viable treatment option for African-American women: Researchers

Breast-conserving therapy is a viable treatment option for African-American women, although they tend to have more advanced breast cancer at diagnosis, according to researchers from Beaumont Hospitals, Royal Oak, Mich. The study is available online now and will be in the July 15 issue of the journal Cancer.

26 May 2010

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

26 May 2010

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

26 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis

ARIAD Pharmaceuticals, Inc. today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Wolf Medical Supply, Inc. and I-Flow Corporation, a division of Kimberly-Clark Corporation, have settled out of court ending the patent dispute regarding the Redi-Flo™ Infusion Pump.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

The National Cancer Coalition is pleased to announce that it recently received a $25,000 grant award from the Hospira Foundation, the philanthropic arm of Hospira, Inc., to support its pharmaceutical relief program within the Dominican Republic. NCC is seeking to significantly increase the levels of medical resources that it provides to the public hospitals of the Dominican Republic in an effort to more fully treat the country's underserved patients, and this grant will contribute toward achieving that goal.

24 May 2010

State roundup: Genetic testing on campus, Texas docs in Mass., and more

"A plan by the University of California, Berkeley to voluntarily test the DNA of incoming freshman has come under fire from critics who said the school was pushing an unproven technology on impressionable students. The university has said it will send test kits to 5,500 new students to analyze genes that help control the body's responses to alcohol, dairy products and folic acid" (Wohlsen, 5/21).

24 May 2010

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

21 May 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

EMEND indication helps women prevent CINV

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Gentium first-quarter net loss decreases to EUR 0.03 million

Carolina Conceptions receives IRB approval to study on new egg freezing technology

Breast-conserving therapy is viable treatment option for African-American women: Researchers

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

State roundup: Genetic testing on campus, Texas docs in Mass., and more

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in